Video Consultation Model Aids Mental Health in Primary Care Patients
By Lori Solomon HealthDay Reporter
WEDNESDAY, Oct. 2, 2024 -- The PROVIDE model of video consultation leads to a decrease in depressive and anxiety symptoms among primary care patients, according to a study published online Sept. 25 in The BMJ.
Markus W. Haun, M.D., from Heidelberg University in Germany, and colleagues evaluated whether an integrated mental health video consultation approach (PROVIDE model) can improve symptoms compared to usual care in adults with depression and anxiety disorders attending primary care. The analysis included 376 adults (aged 18 to 81 years) randomly assigned to the PROVIDE model or usual care.
The researchers found that compared with usual care, the PROVIDE intervention led to improvements in severity of depressive and anxiety symptoms (adjusted mean change difference in the Patient Health Questionnaire Anxiety and Depression Scale score, −2.4 points) at six months. At 12 months, the effects were sustained (−2.9 points).
"Through relatively low intensity treatment, the PROVIDE model led to a decrease in depressive and anxiety symptoms with small effects in the short and long term," the authors write. "Depression and anxiety disorders are prevalent and therefore the small effect might cumulatively impact on population health in this population."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-10-03 06:00
Read more
- Risk for Schizophrenia Increased With ED Visits Involving Hallucinogen Use
- Women, Men on Kidney Dialysis Face Different Heart Risks
- Estimated 100,429 U.S. Youth Living With Pediatric Inflammatory Bowel Disease
- FDA Proposes Ban on a 'Useless' Decongestant, Phenylephrine
- Reading Beyond Headline Rare For Most on Social Media, Study Finds
- Novo Nordisk CEO Warns of Deaths Linked to Compounded Semaglutide
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions